<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2801256767
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1996
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOZOL 40MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        49.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pantozol contains the active substance pantoprazole. Pantozol is a<br />selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the<br />amount of acid produced in your stomach. It is used for treating<br />acid-related diseases of the stomach and intestine.<br />Pantozol is used to treat adults and adolescents 12 years of age<br />and above for<br />&bull; Reflux oesophagitis. An inflammation of your oesophagus<br />(the tube which connects your throat to your stomach)<br />accompanied by the regurgitation of stomach acid.<br />Pantozol is used to treat adults for<br />&bull; An infection with a bacterium called Helicobacter pylori in<br />patients with duodenal ulcers and stomach ulcers in<br />combination with two antibiotics (eradication therapy).<br />The aim is to get rid of the bacteria and so reduce the<br />likelihood of these ulcers returning.<br />&bull; Stomach and duodenal ulcers.<br />&bull; Zollinger-Ellison-Syndrome and other conditions producing<br />too much acid in the stomach.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Pantozol<br />- If you are allergic to pantoprazole or to any of the other<br />ingredients of this medicine (listed in section 6).<br />- If you are allergic to medicines containing other proton pump<br />inhibitors.<br />Take special care with Pantozol<br />- If you have severe liver problems. Please tell your doctor if you<br />ever had problems with your liver in the past. He will check<br />your liver enzymes more frequently, especially when you are<br />taking Pantozol as a long-term treatment. In the case of a rise of<br />liver enzymes the treatment should be stopped.<br />- If you have reduced body stores or risk factors for reduced<br />vitamin B12 and receive long-term treatment with<br />pantoprazole. As with all acid reducing agents, pantoprazole<br />may lead to a reduced absorption of vitamin B12.<br />- If you are taking HIV protease inhibitors such as atazanavir (for<br />the treatment of HIV-infection) at the same time as<br />pantoprazole, ask your doctor for specific advice.<br />- If you get a rash on your skin, especially in areas exposed to the<br />sun tell your doctor as soon as you can, as you may need to stop<br />your treatment with [Pantozol]. Remember to also mention any<br />other ill-effects like pain in your joints.<br />- If you are due to have a specific blood test (Chromogranin A)<br />- Taking a proton pump inhibitor like pantoprazole, especially<br />over a period of more than one year, may slightly increase your<br />risk of fracture in the hip, wrist or spine. Tell your doctor if you<br />have osteoporosis or if you are taking corticosteroids (which<br />can increase the risk of osteoporosis).<br />- If you are on Pantoprazole for more than three months it is<br />possible that the levels of magnesium in your blood may fall.<br />Low levels of magnesium can be seen as fatigue, involuntary<br />muscle contractions, disorientation, convulsions, dizziness,<br />increased heart rate. If you get any of these symptoms, please<br />tell your doctor promptly. Low levels of magnesium can also<br />lead to a reduction in potassium or calcium levels in the blood.<br />Your doctor may decide to perform regular blood tests to<br />monitor your levels of magnesium.<br />Tell your doctor immediately, before or after taking this<br />medicine, if you notice any of the following symptoms, which<br />could be a sign of another, more serious, disease:<br />- an unintentional loss of weight<br />- vomiting, particularly if repeated<br />- vomiting blood; this may appear as dark coffee grounds in your<br />vomit<br />- you notice blood in your stools; which may be black or tarry in<br />appearance<br />- difficulty in swallowing or pain when swallowing<br />- you look pale and feel weak (anaemia)<br />- chest pain<br />- stomach pain<br />- severe and/or persistent diarrhoea, because this medicine has<br />been associated with a small increase in infectious diarrhoea.<br />Your doctor may decide that you need some tests to rule out<br />malignant disease because pantoprazole also alleviates the<br />symptoms of cancer and could cause delay in diagnosing it. If<br />your symptoms continue in spite of your treatment, further<br />investigations will be considered.<br />If you take Pantozol on a long-term basis (longer than 1 year) your<br />doctor will probably keep you under regular surveillance. You<br />should report any new and exceptional symptoms and<br />circumstances whenever you see your doctor.<br />Children and adolescents<br />Pantozol is not recommended for use in children as it has not been<br />proven to work in children below 12 years of age.<br />Other medicines and Pantozol<br />Tell your doctor or pharmacist if you are taking, have recently<br />taken or might take any other medicines, including medicines<br />obtained without a prescription.<br />This is because Pantozol may influence the effectiveness of other<br />medicines, so tell your doctor if you are taking:<br />- Medicines such as ketoconazole, itraconazole and posaconazole<br />(used to treat fungal infections) or erlotinib (used for certain<br />types of cancer) because Pantozol may stop these and other<br />medicines from working properly.<br />- Warfarin and phenprocoumon, which affect the thickening, or<br />thinning of the blood. You may need further checks.<br />- Medicines used to treat HIV-infection, such as atazanavir<br />- Methotrexate (used to treat rheumatoid arthritis, psoriasis, and<br />cancer) &ndash; if you are taking methotrexate your doctor may<br />temporarily stop your Pantozol treatment because pantoprazole<br />can increase levels of methotrexate in the blood.<br />- Fluvoxamine (used to treat depression and other psychiatric<br />diseases &ndash; if you are taking fluvoxamine your doctor may<br />reduce the dose<br />- Rifampicin (used to treat infections)<br />- St John&rsquo;s wort (Hypericum perforatum) (used to treat mild<br />depression)<br />Please tell your doctor or pharmacist if you are taking or have<br />recently taken any other medicines, including medicines obtained<br />without a prescription.<br />Pregnancy and breast-feeding<br />There are no adequate data from the use of pantoprazole in<br />pregnant women. Excretion into human milk has been reported.<br />If you are pregnant or breast feeding, think you may be pregnant,<br />or are planning to have a baby, ask your doctor or pharmacist for<br />advice before taking this medicine.<br />You should use this medicine, only if your doctor considers the<br />benefit for you greater than the potential risk for your unborn<br />child or baby.<br />Driving and using machines<br />Pantozol has no or negligible influence on the ability to drive and<br />use machines.<br />If you experience side effects like dizziness or disturbed vision,<br />you should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist<br />has told you. Check with your doctor or pharmacist if you are not<br />sure.<br />Method of administration<br />Take the tablets 1 hour before a meal without chewing or breaking<br />them and swallow them whole with some water.<br />The recommended dose is:<br />Adults and adolescents 12 years of age and above<br />-To treat reflux oesophagitis<br />The usual dose is one tablet a day. Your doctor may tell you to<br />increase to 2 tablets daily. The treatment period for reflux<br />oesophagitis is usually between 4 and 8 weeks. Your doctor will<br />tell you how long to take your medicine.<br />Adults<br />-For the treatment of an infection with a bacterium called<br />Helicobacter pylori in patients with duodenal ulcers and stomach<br />ulcers in combination with two antibiotics (Eradication therapy).<br />One tablet, two times a day plus two antibiotic tablets of either<br />amoxicillin, clarithromycin and metronidazole (or tinidazole),<br />each to be taken two times a day with your pantoprazole tablet.<br />Take the first pantoprazole tablet 1 hour before breakfast and the<br />second pantoprazole tablet 1 hour before your evening meal.<br />Follow your doctor&rsquo;s instructions and make sure you read the<br />package leaflets for these antibiotics. The usual treatment period<br />is one to two weeks.<br />-For the treatment of stomach and duodenal ulcers.<br />The usual dose is one tablet a day. After consultation with your<br />doctor, the dose may be doubled. Your doctor will tell you how<br />long to take your medicine. The treatment period for stomach<br />ulcers is usually between 4 and 8 weeks. The treatment period for<br />duodenal ulcers is usually between 2 and 4 weeks.<br />-For the long-term treatment of Zollinger-Ellison-Syndrome and<br />of other conditions in which too much stomach acid is produced.<br />The recommended starting dose is usually two tablets a day.<br />Take the two tablets 1 hour before a meal. Your doctor may later<br />adjust the dose, depending on the amount of stomach acid you<br />produce. If prescribed more than two tablets a day, the tablets<br />should be taken twice daily.<br />If your doctor prescribes a daily dose of more than four tablets a<br />day, you will be told exactly when to stop taking the medicine.<br />Patients with kidney problems<br />If you have kidney problems, you should not take Pantozol for<br />eradication of Helicobacter pylori.<br />Patients with liver problems<br />If you suffer from severe liver problems, you should not take<br />more than one tablet 20 mg pantoprazole a day (for this purpose<br />tablets containing 20 mg pantoprazole are available).<br />If you suffer from moderate or severe liver problems, you should<br />not take Pantozol for eradication of Helicobacter pylori.<br />Use in children and adolescents<br />These tablets are not recommended for use in children below 12<br />years.<br />If you take more Pantozol than you should<br />Consult your doctor or pharmacist. There are no known<br />symptoms of overdose.<br />If you forget to take Pantozol<br />Do not take a double dose to make up for a forgotten dose. Take<br />your next, normal dose at the usual time.<br />If you stop taking Pantozol<br />Do not stop taking these tablets without first talking to your doctor<br />or pharmacist.<br />If you have any further questions about the use of this medicine,<br />ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although<br />not everybody gets them.<br />If you get any of the following side effects, stop taking these<br />tablets and tell your doctor immediately, or contact the<br />casualty department at your nearest hospital:<br />- Serious allergic reactions (frequency rare: may affect up to<br />1 in 1,000 people): swelling of the tongue and/or throat,<br />difficulty in swallowing, hives (nettle rash), difficulties in<br />breathing, allergic facial swelling (Quincke&rsquo;s oedema /<br />angioedema), severe dizziness with very fast heartbeat and<br />heavy sweating.<br />- Serious skin conditions (frequency not known: frequency<br />cannot be estimated from the available data): blistering of th<br />e skin and rapid deterioration of your general condition, erosion<br />(including slight bleeding) of eyes, nose, mouth/lips or genitals<br />(Stevens-Johnson-Syndrome, Lyell-Syndrome, Erythema<br />multiforme), and sensitivity to light.<br />- Other serious conditions (frequency not known: frequency<br />cannot be estimated from the available data): yellowing of the<br />skin or whites of the eyes (severe damage to liver cells,<br />jaundice) or fever, rash, and enlarged kidneys sometimes with<br />painful urination, and lower back pain (serious inflammation of<br />the kidneys) , possibly leading to kidney failure.<br />Other side effects are:<br />- Common (may affect up to 1 in 10 people): Benign polyps in<br />the stomach<br />- Uncommon (may affect up to 1 in 100 people)<br />Headache; dizziness; diarrhoea; feeling sick, vomiting;<br />bloating and flatulence (wind); constipation; dry mouth;<br />abdominal pain and discomfort; skin rash, exanthema, eruption;<br />itching; feeling weak, exhausted or generally unwell; sleep<br />disorders; fracture in the hip, wrist or spine.<br />- Rare (may affect up to 1 in 1,000 people)<br />Distortion or complete lack of the sense of taste; disturbances<br />in vision such as blurred vision; hives; pain in the joints;<br />muscle pains; weight changes; raised body temperature; high<br />fever; swelling of the extremities (peripheral oedema); allergic<br />reactions; depression; breast enlargement in males.<br />- Very Rare (may affect up to 1 in 10,000 people)<br />Disorientation.<br />- Not known (frequency cannot be estimated from the available<br />data) Hallucination, confusion (especially in patients with a<br />history of these symptoms); decreased sodium level in blood,<br />decreased magnesium level in blood (see section 2), feeling of<br />tingling, prickling, pins and needles, burning sensation or<br />numbness, rash, possibly with pain in the joints.<br />Side effects identified through blood tests:<br />- Uncommon (may affect up to 1 in 100 people) an increase in<br />liver enzymes.<br />- Rare (may affect up to 1 in 1,000 people)<br />an increase in bilirubin; increased fat levels in blood; sharp<br />drop in circulating granular white blood cells, associated with<br />high fever.<br />- Very Rare (may affect up to 1 in 10,000 people) a reduction in<br />the number of blood platelets, which may cause you to bleed or<br />bruise more than normal; a reduction in the number of white<br />blood cells, which may lead to more frequent infections;<br />coexisting abnormal reduction in the number of red and white<br />blood cells, as well as platelets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on<br />the carton and the container after EXP. The expiry date refers to<br />the last day of that month.<br />Do not store above 30 &deg;C<br />Do not throw away any medicines via wastewater or household<br />waste. Ask your pharmacist how to throw away medicines you no<br />longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is pantoprazole. Each gastro-resistant<br />tablet contains 40 mg of pantoprazole (as sodium<br />sesquihydrate).<br />- The other ingredients are:<br />Core: sodium carbonate (anhydrous), mannitol, crospovidone,<br />povidone K90, calcium stearate. Coating: hypromellose,<br />povidone K25, titanium dioxide (E171), yellow iron oxide<br />(E172), propylene glycol, methacrylic acid ethyl acrylate<br />copolymer (1:1), polysorbate 80, sodium laurilsulfate, triethyl<br />citrate.<br />Printing ink: shellac, red, black and yellow iron oxide (E172),<br />ammonia solution, concentrated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Yellow, oval, biconvex gastro-resistant tablet (tablet) imprinted
with “P 40” on one side.
Pantozol is available in the following pack sizes:
Packs with 7, 15, 30 gastro-resistant tablets
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Acino Pharma AG<br />Birsweg 2, 4253 Liesberg,<br />Switzerland</p><p>&nbsp;</p><p>Manufacturer<br />Takeda GmbH<br />Production site Oranienburg<br />Lehnitzstra&beta;e 70-98<br />16515 Oranienburg / Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">البانتوزول هو دواء &quot;مثبط انتقائي لمضخة البروتون&quot; يعمل على خفض كمية الحمض التي تفرزها المعدة ويستخدم لعلاج أمراض الحموضة بالمعدة والأمعاء. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم البانتوزول لعلاج &nbsp;</strong></p><p dir="RTL"><em>بالنسبة للبالغين والمراهقين من 12 سنة فما فوق: </em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المريء الارتدادي. التهاب المريء (الأنبوب الذي يصل الحلق بالمعدة) المصحوب بارتجاع الأحماض من&nbsp; المعدة.&nbsp;</p><p dir="RTL"><em>بالنسبة للبالغين: </em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بجرثومة تسمى هليكوباكتر بيلوري لدى المرضى الذين يعانون من قرحة المعدة والقرحة الاثنى عشرية بالاتحاد مع مضادين حيويين (العلاج بالاستئصال). والهدف من ذلك التخلص من البكتريا وخفض احتمالية عودة الإصابة بهذه القرح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة المعدة والقرحة الاثنى عشرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة زولينجر إليسون والأمراض الأخرى التي تتسبب في إفراز الكثير من الأحماض داخل المعدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول البانتوزول إذا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الحساسية (فرط الحساسية) تجاه البانتوبرازول أو أي من مكونات بانتوزول الأخرى (انظر القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الحساسية للأدوية التي تحتوي على مثبطات أخرى لمضخة البروتون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات الواجبة عند استخدام البانتوزول </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات حادة في الكبد، يرجى إطلاع طبيبك المعالج إذا كان لديك في أي وقت مضى مشاكل في الكبد، سوف يقوم بفحص إنزيمات الكبد بشكل أكثر انتظاماً وخصوصاً إذا ما كان العلاج بعقار البانتوزول طويل الأجل. يجب في حالة زيادة إنزيمات الكبد توقف العلاج بالبانتوزول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انخفض مخزون الجسم أو عوامل الخطر من نقص فتامين ب12 أثناء الخضوع لعلاج طويل الأجل بـالبانتوبرازول لما قد يؤديه البانتوبرازول شأنه شأن باقي الأدوية الخافضة للحموضة الأخرى من خفض امتصاص فتامين ب12</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواء يحتوي على الأتازانافير (لعلاج الإصابة بمرض الإتش آي في) مع البانتوبرازول، يرجى استشارة طبيبك المعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من طفح جلدي على بشرتك، وبخاصة في المناطق المعرضة للشمس، فأخبر طبيبك بأسرع ما يمكن؛ إذ قد يكون عليك إيقاف علاجك بعقار [بانتوزول]. تذكر أيضًا أن تخبره بأي آثار جانبية أخرى كالآلام في مفاصلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من المقرر إجراء اختبار دم محدد (تحليل بروتين كروموجرانين-أ)قد يؤدي تناوُل مثبط مضخة بروتون مثل بانتوبرازول، خاصةً لفترة أكثر من سنة، إلى زيادة طفيفة في مخاطر حدوث كسر في الورك أو المِعْصَم أو العمود الفقري. اخبر طبيبك إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول كورتيكوستيرويدات (والتي من ممكن أن تُزيد من مخاطر حدوث هشاشة العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول بانتوبرازول لأكثر من ثلاثة أشهر فمن المحتمل أن تنخفض مستويات المغنسيوم لديك في الدم. وتمكن ملاحظة انخفاض مستويات المغنيسيوم من خلال الشعور بالإجهاد، التقلصات اللا إرادية في العضلات، التوهان، التشنجات، الدوخة، زيادة معدل ضربات القلب. إذا عانيت من أيٍ من هذه الأعراض، فيُرجى إخبار طبيبك على الفور. قد تؤدي أيضًا المستويات المنخفضة من المغنسيوم إلى حدوث انخفاض في مستويات اليوتاسيوم أو الكالسيوم في الدم. وقد يقرر طبيبك عمل فحوصات دم منتظمة لمراقبة مستويات المغنيسيوم في الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>راجع طبيبك المعالج على الفور</strong> عند ملاحظة أي من الأعراض التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد الوزن غير المقصود &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء المتكرر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء الدموي، قد يظهر هذا كحبات بُن داكنة في القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشحوب والضعف (فقر الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البراز</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ألم بالصدر</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ألم بالمعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الحاد و/أو المتكرر حيث يرتبط البانتوزول مع زيادة صغيرة في الإسهال العدوائي.&nbsp; &nbsp;</p><p dir="RTL">قد ينصح الطبيب المعالج بإجراء بعض الاختبارات لتفادي الأمراض الخبيثة لأن البانتوبرازول يخفف أيضا من أعراض السرطان وقد يتسبب في تأخير تشخيصه. أما في حالة استمرار ظهور الأعراض بالرغم من العلاج، فقد ينصح بإجراء فحوصات إضافية.</p><p dir="RTL">إذا كان العلاج بالبانتوبرازول لفترة طويلة الأجل (تزيد عن عام واحد)، فقد يبقيك الطبيب المعالج تحت الإشراف الدوري. ويجب عليك أن تبلغ عن أي ظروف أو أعراض جديدة واستثنائية عند مراجعة الطبيب المعالج.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول الأدوية الأخرى </strong></p><p dir="RTL">قد يؤثر البانتوزول على فاعلية الأدوية الأخرى، لذا يرجى إطلاع الطبيب المعالج إذا كنت تتناول&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل الكيتوكونازول والإتراكونازول والبوساكونازول (المستخدم لعلاج الالتهابات الفطرية) أو الإرلوتينب (المستخدم لعلاج أمراض سرطانية محددة) حيث قد يتسبب البانتوزول في وقف فعالية هذه الأدوية وأدوية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورفارين والفينبروكومون اللذين يؤثرا على تثخين الدم وترقيقه. وقد تحتاج إلى إجراء فحوصات أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأتازانافير (المستخدم لعلاج الإصابة بمرض الإتش أي في).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (المُستخدم لعلاج التهاب المفاصل الروماتويدي، والصدفية، والسرطان) &ndash; إذا كنت تتناول ميثوتريكسات، فقد يوقف الطبيب مؤقتًا علاجك بعقار بانتوزول لأنه قد يزيد من مستويات ميثوتريكسات في الدم.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوفوكسامين (المُستخدم لعلاج الاكتئاب وأمراض نفسية الأخرى &ndash; إذا كنت تتناول فلوفوكسامين، فقد يقلل الطبيب من الجرعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (المُستخدم لعلاج العدوى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (الهيوفاريقون) (المستخدمة لعلاج الاكتئاب الطفيف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي إذا كنت تناول أو تناولت مؤخراً أية أدوية أخرى حتى لو لم يتم وصفها لك. &nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">لا تتوفر معلومات وافية عن أثر استخدام البانتوبرازول على المرأة الحامل. تم الإبلاغ عن حالات تم فيها الإفراز في لبن الأم. فإذا كنت حاملاً أو لديك شك بأنك حامل أو مرضعة، لا تستخدمي هذا الدواء إلا إذا رأى الطبيب المعالج أن نفعه سيزيد عن المخاطر المحتملة على الجنين أو الطفل الرضيع.</p><p dir="RTL">استشيري طبيبك المعالج أو الصيدلي قبل تناول أي دواء. &nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات &nbsp;</strong></p><p dir="RTL">ليس لعقار بانتوزول تأثير، أو تأثيره يكاد لا يذكر، على القدرة على القيادة واستخدام الآلات</p><p dir="RTL">إذا عانيت من أعراض جانبية مثل الدوار أو اضطراب الرؤية، يجب عدم القيادة أو تشغيل الآلات.&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء كما وصفه لك الطبيب. يجب مراجعة المعالج أو الصيدلي إذا كنت غير متأكد. &nbsp;</p><p dir="RTL"><strong>متى وكيف تتناول البانتوزول؟ </strong></p><p dir="RTL">يجب تناول الأقراص قبل الأكل بساعة واحدة بدون مضغ أو كسر وبلعها كاملة ببعض الماء.</p><p dir="RTL">ما لم يخبرك طبيبك المعالج بخلاف ذلك، تكون الجرعة المعتادة هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>للبالغين والمراهقين البالغين من العمر 12 عاماً فأكثر: </em></p><p dir="RTL"><strong>لعلاج التهاب المريء الارتدادي</strong></p><p dir="RTL">الجرعة العادية قرص واحد يومياً. قد يصف لك الطبيب زيادة الجرعة إلى قرصين يومياً. وعادة ما تتراوح فترة علاج التهاب المريء الارتدادي بين 4 و8 أسابيع. وسيخبرك الطبيب المعالج عن طول فترة العلاج. &nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><em>البالغين: </em></p><p dir="RTL"><strong>لعلاج الإصابة بجرثومة تسمى هليكوباكتر بيلوري لدى المرضى الذين يعانون من قرحة المعدة والقرحة الاثنى عشرية بالاتحاد مع مضادين حيويين (العلاج بالاستئصال)</strong><strong>:</strong><strong> </strong></p><p dir="RTL">قرص واحد مرتين يومياً بالإضافة إلى قرصين من المضادات الحيوية يومياً إما أموكسيسيلين وكلاريثروميسين وميترونيدازول (أو تينيدازول)، يتم أخذ كل واحد منهما مرتين يومياً مع قرص بانتوبرازول. يتم تناول قرص البانتوبرازول الأول قبل ساعة من إفطار الصباح وتناول قرص البانتوبرازول الثاني قبل ساعة من العشاء. اتبع تعليمات الطبيب وتأكد من قراءة النشرات الداخلية الخاصة بالمضادات الحيوية. عادة ما تتراوح فترة العلاج من أسبوع إلى أسبوعين.&nbsp;</p><p dir="RTL"><strong>لعلاج قرحة المعدة والقرحة الاثنى عشرية</strong><strong>:</strong></p><p dir="RTL">الجرعة العادية قرص واحد يومياً. ويجوز مضاعفة الجرعة بالتشاور مع الطبيب المعالج. سيخبرك الطبيب المعالج بطول فترة العلاج بهذا الدواء. وعادة ما يتراوح علاج قرحة المعدة بين 4 و8 أسابيع. أما علاج القرحة الاثنى عشرية فعادة ما تتراوح بين 2 و4 أسابيع.</p><p dir="RTL">لعلاج متلازمة زولينجر إليسون لفترة طويلة والأمراض الأخرى التي تسبب في إفراز الكثير من الأحماض داخل المعدة:</p><p dir="RTL">الجرعة الأولية الموصى بها هي قرصين يومياً. تناول القرصين قبل ساعة من تناول الطعام. قد يغير الطبيب المعالج فيما بعد من الجرعة وفقاً لكمية الأحماض التي يتم إفرازها داخل المعدة. أما إذا تم وصف أكثر من قرصين يومياً، فحينئذ يجب تناول الأقراص مرتين يومياً. إذا وصف الطبيب المعالج جرعة يومية تزيد عن أربع أقراص، سوف يتم إخبارك عن الموعد المحدد لوقف تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مجموعات معينة من المرضى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت تعاني من مشكلات في الكلية متوسطة أو خطيرة، يجب عدم تناول البانتوزول لاستئصال هليكوباكتر بيلوري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت تعاني من مشكلات خطيرة في الكبد، يجب عدم تناول ما يزيد عن قرص بانتوبرازول 20 ميلي جرام في اليوم (ولهذا الغرض تتوفر أقراص بانتوبرازول 20 ميلي جرام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينصح بتناول هذه الأقراص من قبل الأطفال دون 12 عاماً. &nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من البانتوزول</strong></p><p dir="RTL">اخبر طبيبك المعالج أو الصيدلي، علماً بأنه لا توجد أي أعراض معروفة لتناول جرعة زائدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول البانتوزول </strong></p><p dir="RTL">لا تتناول جرعة مزدوجة لتعويض الجرعة التي نسيت تناولها. وتناول جرعتك العادية التالية في الوقت المعتاد.</p><p>&nbsp;</p><p dir="RTL"><strong>عند إيقاف تناول البانتوزول </strong></p><p dir="RTL">لا تتوقف عن تناول هذه الأقراص بدون استشارة طبيبك المعالج أو الصيدلي.</p><p>إذا كان لديك أي أسئلة إضافية بشأن هذا المنتج، استشر طبيبك المعالج أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثلما هو حال كافة الأدوية الأخرى، فإن بانتوزول قد يتسبب في أعراض جانبية ولكن ليس مع جميع الأشخاص &nbsp;</p><p dir="RTL">يتم تحدد مدى شيوع الأعراض الجانبية المحتملة باستخدام المقياس التالي:</p><p dir="RTL">كثير الشيوع (يصيب أكثر من 1 من كل 10 مستخدمين)</p><p dir="RTL">شائع (يصيب 1 إلى 10 من كل 100 مستخدم)</p><p dir="RTL">غير شائع (يصيب 1 إلى 10 من كل 1000 مستخدم)</p><p dir="RTL">نادر (يصيب 1 إلى 10 من كل 10000 مستخدم)</p><p dir="RTL">شديد الندرة (يصيب أقل من 1 من كل 10000 مستخدم)</p><p dir="RTL">غير معروف (لا يمكن التعرف على مدى شيوعه من البيانات المتاحة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإصابة بأي من الأعراض الجانبية التالية، توقف عن تناول هذه الأقراص واخبر طبيبك المعالج على الفور أو راجع أقرب مستشفى لك: &nbsp;</strong></p><p dir="RTL">- <strong>التفاعلات الأرجية الخطيرة (نادرة التكرار</strong> قد تؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص<strong>):</strong> تورم اللسان و/أو الحلق، صعوبة البلع، الشرى (طفح القراص)، صعوبة التنفس، تورم الوجه الأرجي (وذمة كوينكه/الوذمة الوعائية)، الدوار الحاد المصحوب بضربات القلب السريعة والعرق الشديد.</p><p dir="RTL">- <strong>أمراض الجلد الخطيرة (التكرار غير معروف):</strong> ظهور بثور على الجلد والتدهور السريع للحالة العامة وتآكل (بما في ذلك النزيف الخفيف) العينين أو الأنف أو الفم/الشفتين أو الأعضاء التناسلية (متلازمة ستفين جونسون ومتلازمة ليل والحمامى متعددة الأشكال) والحساسية للضوء.</p><p dir="RTL">- <strong>الأمراض الأخرى الخطيرة (التكرار غير معروف):</strong> اصفرار الجلد أو بياض العينين (الضرر البالغ بخلايا الكبد، اليرقان) أو الحمى أو الطفح الجلدي وتضخم الكلية المصحوبة في بعض الأحيان بعسرة التبول وألم أسفل الظهر (التهاب الكليتين الخطير، قد تؤدي إلى حدوث فشل كلوي.)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الأعراض الجانبية الأخرى:</p><p dir="RTL"><strong>-&nbsp;&nbsp; شائعة </strong>(قد تُؤثر على شخص واحد من بين كل 10&nbsp;أشخاص): سلائل حميدة في المعدة&nbsp; &nbsp;&nbsp;&nbsp;</p><p dir="RTL">- <strong>غير الشائعة</strong> (تصيب 1 إلى 10 من كل 1000 مستخدم)</p><p dir="RTL">الصداع، الدوار، الإسهال، الغثيان، القيء، النفخ وتطبل البطن (الريح)، الإمساك، جفاف الفم، ألم واضطراب البطن، الطفح الجلدي، الطفيحة، البزوغ، الحكة؛ الشعور بالوهن أو الاجهاد أو التعب عموماً؛ اضطرابات النوم. &nbsp;</p><p dir="RTL">إن تناول الأدوية المثبطة لمضخة البروتون مثل البانتوبرازول وتحديداً لمدة تزيد عن عام واحد قد يزيد من مخاطر الإصابة بكسر في الورك أو المعصم أو العمود الفقري. يجب إخبار الطبيب إذا كنت تعاني من هشاشة العظام أو تتعاطى أياً من الستيرويدات القشرية (التي قد تزيد من مخاطر الإصابة بهشاشة العظام). &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">- <strong>النادرة</strong> (تصيب 1 إلى 10 من كل 10000 مستخدم)</p><p dir="RTL">اضطراب أو فقدان حاسة التذوق؛ اضطرابات الرؤية مثل عدم وضوح الرؤية، الشرى، ألم المفاصل، ألم العضلات، تغييرات الوزن، ارتفاع حرارة الجسم، الحمى الشديدة، تورم الأطراف (الوذمة المحيطية)؛ التفاعلات الأرجية، الاكتئاب، كبر الصدرين لدى الرجال. &nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">- <strong>شديد الندرة</strong> (تصيب أقل من 1 من كل 10000 مستخدم)</p><p dir="RTL">ضعف التركيز</p><p dir="RTL">- <strong>غير معروف</strong> (لا يمكن التعرف على مدى شيوعه من البيانات المتاحة)</p><p dir="RTL">الهلوسة، الارتباك (وخصوصاً للمرضى الذين لديهم تاريخ بهذه الأعراض) انخفاض نسبة الصوديوم في الدم.</p><p dir="RTL">قد ينخفض مستوى الماغنسيوم في الدم في حالة تعاطي عقار بانتوزول لمدة تزيد عن ثلاثة أشهر. وتتضمن أعراض انخفاض مستوى الماغنسيوم في الدم: الإجهاد والتقلص العضلي اللاإرادي والاضطراب والتشنجات والدوخة وارتفاع معدل ضربات القلب. فعند الإصابة بهذه الأعراض، التمس المشورة من الطبيب المعالج على الفور. ويمكن أن يؤدي انخفاض مستوى الماغنسيوم في الدم أيضاً إلى انخفاض مستوى البوتاسيوم أو الكالسيوم في الدم. وقد يقرر الطبيب المعالج إجراء فحوصات دم دورية لمراقبة نسبة الماغنسيوم في الدم.&nbsp; &nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية المكتشفة عن طريق اختبارات الدم: </strong></p><p dir="RTL">- <strong>غير الشائعة</strong> (تصيب 1 إلى 10 من كل 1000 مستخدم)</p><p dir="RTL">زيادة إنزيمات الكبد</p><p dir="RTL">- <strong>النادرة</strong> (تصيب 1 إلى 10 من كل 10000 مستخدم)</p><p dir="RTL">زيادة البِيليروبين، زيادة نسبة الدهون في الدم، الانخفاض الحاد في دوران كريات الدم البيضاء الحبيبية المصحوب بالحمى الشديدة</p><p dir="RTL">- <strong>شديدة الندرة</strong> (تصيب أقل من 1 من كل 10000 مستخدم)</p><p dir="RTL">انخفاض عدد الصفائح الدموية الذي قد يؤدي إلى زيادة النزيف أو الكدمات عن المعتاد، انخفاض عدد كريات الدم البيضاء الذي قد يؤدي إلى حالات العدوى المتكررة، الانخفاض غير الطبيعي والمتزامن لعدد كريات الدم البيضاء والحمراء فضلاً عن الصفائح الدموية. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا أصبح أي من الآثار الجانبية خطير أو في حالة إصابتك بأية أعراض جانبية غير مذكورة في هذه النشرة، استشر الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول و مرآى الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة . يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر.</p><p dir="RTL">يحفظ في درجة حرارة لاتزيد عن 30 درجة مئوية.</p><p dir="RTL">لا يجوز إلقاء الأدوية في مياه الصرف أو المخلفات المنزلية. استشر الصيدلي حول كيفية التخلص من الأدوية عند عدم الاحتياج إليها. تساعدك هذه الإجراءات على حماية البيئة. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات البانتوزول </strong></p><p dir="RTL">المركب الفعال هو البانتوبرازول. كل قرص مقاوم لعصارة المعدة<strong> </strong>يحتوي على 40 ميلي جرام من البانتوبرازول (على شكل صوديوم سيسكويهيدريت).</p><p dir="RTL">- المكونات الأخرى:</p><p dir="RTL">قلب المنتج: كربونات الصوديوم (الخالية من الماء)، مانيتول، كروسبفيدون، بوفيدون كيه 90، استيارات الكالسيوم.</p><p dir="RTL">الغلاف: هايبروميلوز، بوفيدون كيه 25، ثاني أكسيد التيتانيوم (إي 171)، أكسيد الحديد الأصفر (إي 172)، غليكول البروبيلين، كوبوليمر حامض ميثاكريليك - أثيل أكريليت (1:1)، بوليسوربات 80، لوريلسولفات الصوديوم، ثلاثي إثيل السترات.</p><p>حبر الطباعة: شيلاك، أكسيد الحديد الأصفر والأسود والأحمر (إي 172)، محلول الأمونيا، مركز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قرص مقاوم لعصارة المعدة بيضاوي الشكل ومحدب الوجيهين وأصفر اللون مطبوع على أحد جانبيه عبارة &ldquo;P 40&rdquo;</p><p dir="RTL">يتوفر البانتوزول في أحجام العبوات التالية: 7، 15، 30 قرص مقاوم لعصارة المعدة. ليست كل العبوات متداولة في جميع البلاد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لترخيص التسويق: </strong></p><p>Takeda GmbH</p><p>Byk-Gulden-Str. 2</p><p>D-78467 Konstanz , Germany</p><p>tel: + 49 7531 84 0</p><p>fax: + 49 7531 84 2474</p><p>e-mail: customer-servicecenter@takeda.com</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة </strong></p><p>Takeda GmbH</p><p>Production site Oranienburg</p><p>Lehnitzstra&szlig;e 70 - 98</p><p>16515 Oranienburg</p><p>Germany</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pantozol 40 mg gastro-resistant tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistant tablet contains 40 mg of pantoprazole (as sodium sesquihydrate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant tablet (tablet).
Yellow, oval, biconvex film-coated tablet imprinted with “P 40” in brown ink on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantozol 40 mg is indicated for use in adults and adolescents 12 years of age and above for:<br />&minus; Reflux oesophagitis.<br />Pantozol 40 mg is indicated in adults for:<br />&minus; Eradication of Helicobacter pylori (H. pylori) in combination with appropriate antibiotic therapy in<br />patients with H. pylori associated ulcers.<br />&minus; Gastric and duodenal ulcer.<br />&minus; Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults and adolescents 12 years of age and above<br />Reflux oesophagitis<br />One tablet of Pantozol 40 mg per day. In individual cases the dose may be doubled (increase to 2 tablets<br />Pantozol 40 mg daily) especially when there has been no response to other treatment. A 4-week period is<br />usually required for the treatment of reflux oesophagitis. If this is not sufficient, healing will usually be<br />achieved within a further 4 weeks.<br />Adults<br />Eradication of H. pylori in combination with two appropriate antibiotics<br />In H. pylori positive patients with gastric and duodenal ulcers, eradication of the germ by a combination<br />therapy should be achieved. Considerations should be given to official local guidance (e.g. national<br />recommendations) regarding bacterial resistance and the appropriate use and prescription of antibacterial<br />agents. Depending upon the resistance pattern, the following combinations can be recommended for the<br />eradication of H. pylori:<br />a) twice daily one tablet Pantozol 40 mg<br />+ twice daily 1000 mg amoxicillin<br />+ twice daily 500 mg clarithromycin<br />2<br />b) twice daily one tablet Pantozol 40 mg<br />+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)<br />+ twice daily 250 - 500 mg clarithromycin<br />c) twice daily one tablet Pantozol 40 mg<br />+ twice daily 1000 mg amoxicillin<br />+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)<br />In combination therapy for eradication of H. pylori infection, the second Pantozol 40 mg tablet should be<br />taken 1 hour before the evening meal. The combination therapy is implemented for 7 days in general and<br />can be prolonged for a further 7 days to a total duration of up to two weeks. If, to ensure healing of the<br />ulcers, further treatment with pantoprazole is indicated, the dose recommendations for duodenal and<br />gastric ulcers should be considered.<br />If combination therapy is not an option, e.g. if the patient has tested negative for H. pylori, the following<br />dose guidelines apply for Pantozol 40 mg monotherapy:<br />Treatment of gastric ulcer<br />One tablet of Pantozol 40 mg per day. In individual cases the dose may be doubled (increase to 2 tablets of<br />Pantozol 40 mg daily) especially when there has been no response to other treatment. A 4-week period is<br />usually required for the treatment of gastric ulcers. If this is not sufficient, healing will usually be achieved<br />within a further 4 weeks.<br />Treatment of duodenal ulcer<br />One tablet of Pantozol 40 mg per day. In individual cases the dose may be doubled (increase to 2 tablets of<br />Pantozol 40 mg daily) especially when there has been no response to other treatment. A duodenal ulcer<br />generally heals within 2 weeks. If a 2-week period of treatment is not sufficient, healing will be achieved<br />in almost all cases within a further 2 weeks.<br />Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions<br />For the long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory<br />conditions patients should start their treatment with a daily dose of 80 mg (2 tablets of Pantozol 40 mg<br />40 mg). Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid<br />secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A<br />temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer<br />than required for adequate acid control.<br />Treatment duration in Zollinger-Ellison syndrome and other pathological hypersecretory conditions is not<br />limited and should be adapted according to clinical needs.<br />Patients with hepatic impairment<br />A daily dose of 20 mg pantoprazole (1 tablet of 20 mg pantoprazole) should not be exceeded in patients<br />with severe liver impairment. Pantozol 40 mg must not be used in combination treatment for eradication<br />of H. pylori in patients with moderate to severe hepatic dysfunction since currently no data are available<br />on the efficacy and safety of Pantozol 40 mg in combination treatment of these patients (see section 4.4).<br />Patients with renal impairment<br />No dose adjustment is necessary in patients with impaired renal function. Pantozol 40 mg must not be<br />used in combination treatment for eradication of H. pylori in patients with impaired renal function since<br />currently no data are available on the efficacy and safety of Pantozol 40 mg in combination treatment for<br />these patients (see section 5.2).<br />3<br />Older people<br />No dose adjustment is necessary in older people (see section 5.2).<br />Paediatric population<br />Pantozol 40 mg is not recommended for use in children below 12 years of age because of limited data on<br />safety and efficacy in the age group (see section 5.2).<br />Method of administration<br />Oral use<br />The tablets should not be chewed or crushed, and should be swallowed whole 1 hour before a meal with<br />some water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, any of the other excipients listed in
section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hepatic impairment<br />In patients with severe liver impairment, the liver enzymes should be monitored regularly during treatment<br />with pantoprazole, particularly on long-term use. In the case of a rise of the liver enzymes, the treatment<br />should be discontinued (see section 4.2).<br />Combination therapy<br />In the case of combination therapy, the summaries of product characteristics of the respective medicinal<br />products should be observed.<br />Gastric malignancy<br />Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay<br />diagnosis. In the presence of any alarm symptom (e. g. significant unintentional weight loss, recurrent<br />vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present,<br />malignancy should be excluded.<br />Further investigation is to be considered if symptoms persist despite adequate treatment.<br />Co-administration with HIV protease inhibitors<br />Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption<br />is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their<br />bioavailability (see section 4.5).<br />Influence on vitamin B12 absorption<br />In patients with Zollinger-Ellison syndrome and other pathological hypersecretory conditions requiring<br />long-term treatment, pantoprazole, as all acid-blocking medicines, may reduce the absorption of<br />vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with<br />reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if<br />respective clinical symptoms are observed.<br />Long term treatment<br />In long-term treatment, especially when exceeding a treatment period of 1 year, patients should be kept<br />under regular surveillance.<br />4<br />Gastrointestinal infections caused by bacteria<br />Treatment with Pantozol 40 mg may lead to a slightly increased risk of gastrointestinal infections caused<br />by bacteria such as Salmonella and Campylobacter or C. difficile.<br />Hypomagnesaemia<br />Severe hypomagnesaemia has been reported in patients treated with PPIs like pantoprazole for at least<br />three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue,<br />tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin<br />insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium<br />replacement and discontinuation of the PPI.<br />For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products<br />that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring<br />magnesium levels before starting PPI treatment and periodically during treatment.<br />Bone fractures<br />Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly<br />increase the risk of hip, wrist and spine fracture, predominantly in older people or in the presence of other<br />recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall<br />risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of<br />osteoporosis should receive care according to current clinical guidelines and they should have an adequate<br />intake of vitamin D and calcium.<br />Subacute cutaneous lupus erythematosus (SCLE)<br />Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in<br />sun exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help<br />promptly and the healthcare professional should consider stopping Pantozol 40 mg. SCLE after previous<br />treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.<br />Interference with Laboratory Tests<br />Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To<br />avoid this interference, Pantozol 40 mg treatment should be stopped for at least 5 days before CgA<br />measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial<br />measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor<br />treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicinal products with pH-Dependent Absorption Pharmacokinetics<br />Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with<br />the absorption of other medicinal products where gastric pH is an important determinant of oral<br />availability, e.g. some azole antifungals such as ketoconazole, itraconazole, posaconazole and other<br />medicine such as erlotinib.<br />HIV protease inhibtiors<br />Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption<br />is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their<br />bioavailability (see section 4.4).<br />If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable, close<br />clinical monitoring (e.g virus load) is recommended. . A pantoprazole dose of 20 mg per day should not be<br />exceeded. Dosage of the HIV protease inhibitors may need to be adjusted.<br />5<br />Coumarin anticoagulants (phenprocoumon or warfarin)<br />Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of<br />warfarin, phenprocoumon or INR. However, there have been reports of increased INR and prothrombin<br />time in patients receiving PPIs and warfarin or phenprocoumon concomitantly. Increases in INR and<br />prothrombin time may lead to abnormal bleeding, and even death. Patients treated with pantoprazole and<br />warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time..<br />Methotrexate<br />Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to<br />increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used,<br />for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.<br />Other interactions studies<br />Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main<br />metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by<br />CYP3A4.<br />Interaction studies with medicinal products also metabolized with these pathways, like carbamazepine,<br />diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl<br />oestradiol, did not reveal clinically significant interactions.<br />An interaction of pantoprazole with other medicinal products or compounds, which are metabolized using<br />the same enzyme system, cannot be excluded.<br />Results from a range of interaction studies demonstrate that pantoprazole does not affect the metabolism<br />of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as<br />piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol), or does not<br />interfere with p-glycoprotein related absorption of digoxin.<br />There were no interactions with concomitantly administered antacids.<br />Interaction studies have also been performed by concomitantly administering pantoprazole with the<br />respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions<br />were found.<br />Medicinal products that inhibit or induce CYP2C19:<br />Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose<br />reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with<br />hepatic impairment.<br />Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (Hypericum<br />perforatum) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme<br />systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no<br />malformative or feto/ neonatal toxicity of Pantozol 40 mg.<br />Animal studies have shown reproductive toxicity (see section 5.3).<br />As a precautionary measure, it is preferable to avoid the use of Pantozol 40 mg during pregnancy.<br />6<br />Breast-feeding<br />Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on<br />the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to<br />the newborns/infants cannot be excluded. Therefore, a decision on whether to discontinue breast-feeding<br />or to discontinue/abstain from Pantozol 40 mg therapy taking into account the benefit of breast-feeding<br />for the child, and the benefit of Pantozol 40 mg therapy for the woman.<br />Fertility<br />There was no evidence of impaired fertility following the administration of pantoprazole in animal studies<br />(see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole has no or negligible influence on the ability to drive and use machines.<br />Adverse drug reactions, such as dizziness and visual disturbances may occur (see section 4.8). If affected,<br />patients should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs). The most<br />commonly reported ADRs are diarrhoea and headache, both occurring in approximately 1 % of patients.<br />The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency<br />classification:<br />Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to<br />&lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).<br />For all adverse reactions reported from post-marketing experience, it is not possible to apply any Adverse<br />Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />Table 1. Adverse reactions with pantoprazole in clinical trials and post-marketing experience<br />Frequency<br />System<br />Organ Class<br />Common Uncommon Rare Very rare Not known<br />Blood and<br />lymphatic system<br />disorders<br />Agranulocytosis Thrombocytopenia;<br />Leukopenia;<br />Pancytopenia<br />Immune system<br />disorders<br />Hypersensitivity<br />(including<br />anaphylactic<br />reactions and<br />anaphylactic<br />shock)<br />Metabolism and<br />nutrition<br />disorders<br />Hyperlipidaemias<br />and lipid<br />increases<br />(triglycerides,<br />cholesterol);<br />Weight changes<br />Hyponatraemia;<br />Hypomagnesaemia<br />(see section 4.4);<br />Hypocalcaemia (1);<br />Hypokalaemia<br />Psychiatric Sleep disorders Depression (and Disorientation (and Hallucination;<br />Frequency<br />System<br />Organ Class<br />Common Uncommon Rare Very rare Not known<br />disorders all aggravations) all aggravations) Confusion<br />(especially in predisposed<br />patients,<br />as well as the<br />aggravation of<br />these symptoms in<br />case of preexistence)<br />Nervous system<br />disorders<br />Headache;<br />Dizziness<br />Taste disorders Parasthesia<br />Eye disorders Disturbances in<br />vision / blurred<br />vision<br />Gastrointestinal<br />disorders<br />Fundic<br />gland<br />polyps<br />(benign)<br />Diarrhoea;<br />Nausea /<br />vomiting;<br />Abdominal<br />distension and<br />bloating;<br />Constipation;<br />Dry mouth;<br />Abdominal<br />pain and<br />discomfort<br />Microscopic<br />colitis<br />Hepatobiliary<br />disorders<br />Liver enzymes<br />increased<br />(transaminases,<br />&gamma;-GT)<br />Bilirubin<br />increased<br />Hepatocellular<br />injury; Jaundice;<br />Hepatocellular<br />failure<br />Skin and subcutaneous<br />tissue<br />disorders<br />Rash /<br />exanthema /<br />eruption;<br />Pruritus<br />Urticaria;<br />Angioedema<br />Stevens-Johnson<br />syndrome; Lyell<br />syndrome;<br />Erythema<br />multiforme;<br />Photosensitivity;<br />Subacute<br />cutaneous lupus<br />erythematosus (see<br />section 4.4)<br />Musculoskeletal<br />and connective<br />tissue disorders<br />Fracture of the<br />hip, wrist or<br />spine (see<br />section 4.4)<br />Arthralgia;<br />Myalgia<br />Muscle spasm (2)<br />Renal and<br />urinary disorders<br />Interstitial<br />nephritis (with<br />possible<br />progression to<br />renal failure)<br />Reproductive<br />system and<br />breast<br />Gynaecomastia<br />Frequency<br />System<br />Organ Class<br />Common Uncommon Rare Very rare Not known<br />disorders<br />General disorders<br />and<br />administration<br />site conditions<br />Asthenia,<br />fatigue and<br />malaise<br />Body<br />temperature<br />increased;<br />Oedema<br />peripheral<br />1. Hypocalcemia in association with hypomagnesemia<br />2. Muscle spasm as a consequence of electrolyte disturbance<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows<br />continued monitoring of the benefit/risk balance of the medical product. Healthcare professionals are<br />asked to report any suspected adverse reactions via Bundesinstitut f&uuml;r Arzneimittel und Medizinprodukte<br />Abt. Pharmakovigilanz<br />Kurt-Georg-Kiesinger-Allee 3<br />53175 Bonn<br />Website: www.bfarm.de.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.<br />Systemic exposure with up to 240 mg administered intravenously over 2 minutes, were well tolerated.<br />As pantoprazole is extensively protein bound, it is not readily dialysable.<br />In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive<br />treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC02<br />Mechanism of action<br />Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the<br />stomach by specific blockade of the proton pumps of the parietal cells.<br />Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits<br />the H+, K+-ATPase enzyme, i.e. the final stage in the production of hydrochloric acid in the stomach. The<br />inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients,<br />freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and<br />H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases<br />gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole<br />binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion<br />independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same<br />whether the product is given orally or intravenously.<br />Pharmacodynamic effects<br />The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not<br />exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An<br />excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the<br />number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during longterm<br />treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far,<br />the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal<br />experiments (see section 5.3) have not been observed in humans.<br />An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled<br />out on endocrine parameters of the thyroid according to results in animal studies.<br />During treatment with antisecretory medicinal products, serum gastrin increases in response to the<br />decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level<br />may interfere with investigations for neuroendocrine tumours.<br />Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days<br />and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated<br />following PPI treatment to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Pantoprazole is rapidly absorbed and the maximal plasma concentration is achieved even after one single<br />40 mg oral dose. On average at about 2.5 h p.a. the maximum serum concentrations of about 2 - 3 &mu;g/ml<br />are achieved, and these values remain constant after multiple administration.<br />Pharmacokinetics does not vary after single or repeated administration. In the dose range of 10 to 80 mg,<br />the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.<br />The absolute bioavailability from the tablet was found to be about 77 %. Concomitant intake of food had<br />no influence on AUC, maximum serum concentration and thus bioavailability. Only the variability of the<br />lag-time will be increased by concomitant food intake.<br />Distribution<br />Pantoprazole&#39;s serum protein binding is about 98 %. Volume of distribution is about 0.15 l/kg.<br />Biotransformation<br />The substance is almost exclusively metabolized in the liver. The main metabolic pathway is<br />demethylation by CYP2C19 with subsequent sulphate conjugation, other metabolic pathway includes<br />oxidation by CYP3A4.<br />Elimination<br />Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of subjects<br />with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the<br />parietal cell the elimination half-life does not correlate with the much longer duration of action (inhibition<br />of acid secretion).<br />Renal elimination represents the major route of excretion (about 80 %) for the metabolites of<br />pantoprazole, the rest is excreted with the faeces. The main metabolite in both the serum and urine is<br />desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite (about<br />1.5 hours) is not much longer than that of pantoprazole.<br />Special populations<br />Poor metabolisers<br />Approximately 3 % of the European population lack a functional CYP2C19 enzyme and are called poor<br />metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalysed by<br />CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma<br />concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a<br />functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased<br />by about 60 %. These findings have no implications for the posology of pantoprazole.<br />Renal impairment<br />No dose reduction is recommended when pantoprazole is administered to patients with impaired renal<br />function (including dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very<br />small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed halflife<br />(2 - 3 h), excretion is still rapid and thus accumulation does not occur.<br />Hepatic impairment<br />Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values<br />increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum serum<br />concentration only increased slightly by a factor of 1.5 compared with healthy subjects.<br />Older people<br />A slight increase in AUC and Cmax in elderly volunteers compared with younger counterparts is also not<br />clinically relevant.<br />Paediatric population<br />Following administration of single oral doses of 20 or 40 mg pantoprazole to children aged 5 - 16 years<br />AUC and Cmax were in the range of corresponding values in adults.<br />Following administration of single i.v. doses of 0.8 or 1.6 mg/kg pantoprazole to children aged<br />2 - 16 years there was no significant association between pantoprazole clearance and age or weight. AUC<br />and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard to humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity and genotoxicity.<br />In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition,<br />squamous cell papillomas were found in the forestomach of rats. The mechanism leading to the formation<br />of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the<br />conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat<br />during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumors<br />was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic<br />rate in the liver.<br />A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the<br />highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazole-induced<br />changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful<br />effects on the thyroid glands are expected.<br />In a peri-postnatal rat reproduction study designed to assess bone development, signs of offspring toxicity<br />(mortality, lower mean body weight, lower mean body weight gain and changes in bone parameters) were<br />observed at exposures (Cmax) approximately 2x the human clinical exposure. Changes in bone parameters<br />were considered secondary to overall growth suppression and not direct effects on bone development. By<br />the end of the recovery phase, bone parameters were similar across groups and body weights were also<br />trending toward reversibility after a drug-free recovery period. A previous peri-postnatal study in rats at<br />slightly lower doses found no adverse effects at 3 mg/kg compared with a low dose of 5 mg/kg in this<br />study.<br />Investigations revealed no evidence of impaired fertility or teratogenic effects.<br />Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation.<br />As a result, concentration of pantoprazole in the foetus is increased shortly before birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core:<br />Sodium carbonate, anhydrous<br />Mannitol (E421)<br />Crospovidone<br />Povidone K90<br />Calcium stearate<br />Coating:<br />Hypromellose<br />Povidone K25<br />Titanium dioxide (E171)<br />Yellow iron oxide (E172)<br />Propylene glycol<br />Methacrylic acid-ethyl acrylate copolymer (1:1)<br />Polysorbate 80<br />Sodium laurilsulfate<br />Triethyl citrate<br />Printing ink:<br />Shellac<br />Red iron oxide (E172)<br />Black iron oxide (E172)<br />Yellow iron oxide (E172)<br />Ammonia solution, concentrated</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Blister packs
3 years.
Bottles
Unopened: 3 years.
After first opening: [to be completed nationally]
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottles with LDPE screw cap closure.<br />7 gastro-resistant tablets<br />10 gastro-resistant tablets<br />14 gastro-resistant tablets<br />15 gastro-resistant tablets<br />24 gastro-resistant tablets<br />28 gastro-resistant tablets<br />30 gastro-resistant tablets<br />48 gastro-resistant tablets<br />49gastro-resistant tablets<br />56 gastro-resistant tablets<br />60 gastro-resistant tablets<br />84 gastro-resistant tablets<br />90 gastro-resistant tablets<br />98 gastro-resistant tablets<br />98 (2x49) gastro-resistant tablets<br />100 gastro-resistant tablets<br />Hospital pack with 50 gastro-resistant tablets<br />90 gastro-resistant tablets<br />100 gastro-resistant tablets<br />140 gastro-resistant tablets<br />140 (10x14) gastro-resistant tablets<br />150 (10x15) gastro-resistant tablets<br />700 (5x140) gastro-resistant tablets<br />Blister (ALU/ALU blister) without cardboard reinforcement.<br />Blister (ALU/ALU blister) with cardboard reinforcement (blister wallet).<br />7 gastro-resistant tablets<br />10 gastro-resistant tablets<br />14 gastro-resistant tablets<br />15 gastro-resistant tablets<br />28 gastro-resistant tablets<br />30 gastro-resistant tablets<br />49gastro-resistant tablets<br />56 gastro-resistant tablets<br />60 gastro-resistant tablets<br />84 gastro-resistant tablets<br />90 gastro-resistant tablets<br />98 gastro-resistant tablets<br />98 (2x49) gastro-resistant tablets<br />100 gastro-resistant tablets<br />112 gastro-resistant tablets<br />168 gastro-resistant tablets<br />Hospital pack with 50 gastro-resistant tablets<br />90 gastro-resistant tablets<br />100 gastro-resistant tablets<br />140 gastro-resistant tablets<br />140 (10x14) gastro-resistant tablets<br />150 (10x15) gastro-resistant tablets<br />700 (5x140) gastro-resistant tablets<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acino Pharma AG
Birsweg 2, 4253 Liesberg
Switzerland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>